Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer

Free Subscription 30.03.2026 1 Abdom Radiol (NY) 1 Adv Healthc Mater 1 Anal Chem 1 Ann Work Expo Health 1 BJU Int 1 BMC Cancer 1 BMJ Case Rep 1 Br J Radiol 1 Cancer 1 Cancer Immunol Immunother 1 Cancer Med 1 Clin Genitourin Cancer 1 Discov Oncol 1 EMBO Rep 1 Environ Health (Wash) 2 Eur Urol 1 Eur Urol Oncol 1 Front Immunol 1 Histol Histopathol 1 Hu Li Za Zhi 1 Int Braz J Urol 1 Int J Biol Macromol 1 Int J Hyperthermia 1 Int J Nanomedicine 1 Int J Urol 1 Int Urol Nephrol 1 Ir Med J 1 J Int Med Res 1 J Pediatr Hematol Oncol 1 J Toxicol Environ Health A 1 J Urol 1 JCO Oncol Pract 1 Lakartidningen 1 Minerva Urol Nephrol 1 Mol Imaging Biol 1 Nat Commun 1 Oncogene 1 Res Rep Urol 1 Scand J Urol 1 Sci Rep 1 Support Care Cancer 1 Surg Today 1 Ther Adv Urol 2 Urol Oncol 1 Urologie

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Abdom Radiol (NY)

1. SALVAGGIO G, Comelli A, Albano D, Galia M, et al
   Artificial intelligence and radiomics in bladder cancer MRI: a scoping review of applications, performance, and barriers to clinical translation.
   Abdom Radiol (NY). 2026 Mar 24. doi: 10.1007/s00261-026-05457.
   PubMed         Abstract available
   
   

   
   Adv Healthc Mater

2. LU Z, Yang W, Hong Y, Qiao Y, et al
   Delivery of Multifunctional Microspheres via Intravesical Instillation for Bladder Carcinoma: Therapeutic Potential and Mechanistic Insights.
   Adv Healthc Mater. 2026;15:e04290.
   PubMed         Abstract available
   
   

   
   Anal Chem

3. QIAO S, Li Y, Gao Y, Li K, et al
   Point-of-Care Detection of Dual Methylation Genes for Rapid Bladder Cancer Diagnosis and Prognosis.
   Anal Chem. 2026 Mar 26. doi: 10.1021/acs.analchem.6c00373.
   PubMed         Abstract available
   
   

   
   Ann Work Expo Health

4. FRIESEN MC, Xie S, Locke SJ, Baris D, et al
   Enhancing a job exposure matrix with subject-specific information to assess combined exposure to benzene, toluene, and xylene in a case-control study.
   Ann Work Expo Health. 2026;70:wxag014.
   PubMed         Abstract available
   
   

   
   BJU Int

5. YE T, Tura B, Abbotts B, Zeegers MP, et al
   Clinical outcomes of BCG-treated patients with high-risk non-muscle-invasive bladder cancer according to pre- and post-2021 European Association of Urology risk classifications.
   BJU Int. 2026 Mar 23. doi: 10.1111/bju.70247.
   PubMed        
   
   

   
   BMC Cancer

6. HUO X, Qi J, Zhu Y, Song H, et al
   Integrative analysis of adenosine-related RNA modifications defines molecular subtypes of bladder cancer and identifies CES1 as a driver of tumor progression and immunotherapy resistance.
   BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15897.
   PubMed        
   
   

   
   BMJ Case Rep

7. NGUYEN ME MD, Cepek J MD, PhD, FRCPC, Charlebois J MD FRCPC, Rosebush P MD, FRCPC, et al
   Elevations in serum lithium levels postcystectomy and ileal conduit.
   BMJ Case Rep. 2026;19:e267862.
   PubMed         Abstract available
   
   

   
   Br J Radiol

8. RUAN JL, Lee C, Sharma O, Lovgren N, et al
   FLASH radiotherapy enables dose escalation and improves survival in an orthotopic muscle-invasive bladder cancer mouse model.
   Br J Radiol. 2026 Mar 26:tqag071. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Cancer

9. WU Z, Cao L, Zeng J, Feng W, et al
   Diagnostic performance analysis of two-gene methylation in urothelial carcinoma based on small-volume urine sample.
   Cancer. 2026;132:e70373.
   PubMed         Abstract available
   
   

   
   Cancer Immunol Immunother

10. MOLLICA V, Massari F, Fujita K, Giannatempo P, et al
    Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).
    Cancer Immunol Immunother. 2026;75:119.
    PubMed         Abstract available
    
    

    
    Cancer Med

11. YAN X, Tang X, Guo L, He Z, et al
    Characterization of Immune Infiltrating Cells in Bladder Urothelial Carcinoma and Its Clinical Significance.
    Cancer Med. 2026;15:e71737.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

12. RAIZENNE BL, Koshkin VS, Zhu A, Ben-David R, et al
    Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026;24:102524.
    PubMed        
    
    

    
    Discov Oncol

13. XU L, Zeng Z, Zou X, Zhu Z, et al
    Construction and evaluation of a bladder cancer prognosis model based on super-enhancer-associated genes.
    Discov Oncol. 2026 Mar 23. doi: 10.1007/s12672-026-04851.
    PubMed         Abstract available
    
    

    
    EMBO Rep

14. KOCH J, Xu J, Bormann F, Coutinho Carneiro V, et al
    The bladder cancer m(6)A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylation.
    EMBO Rep. 2026 Mar 23. doi: 10.1038/s44319-026-00739.
    PubMed         Abstract available
    
    

    
    Environ Health (Wash)

15. XIAO Y, Zhang J, Jia Y, Song H, et al
    Cigarette Smoking-Regulated PRKCE Is Involved in Bladder Cancer Susceptibility through cGMP/PKG-Dependent Glycolysis.
    Environ Health (Wash). 2025;4:365-378.
    PubMed         Abstract available
    
    

    
    Eur Urol

16. CONTIERI R, Lazzeri M, Perdona S, Hurle R, et al
    Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1
    Eur Urol. 2026 Mar 20:S0302-2838(26)02038-5. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
17. KITAMURA H, Nishiyama H
    Reply to Roberto Contieri, Massimo Lazzeri, Sisto Perdona, and Rodolfo Hurle's Letter to the Editor re: Kitamura, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Nega
    Eur Urol. 2026 Mar 20:S0302-2838(26)02039-7. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Eur Urol Oncol

18. KLINGENBERG S, Lindgren MS, Jakobsen JK, Jensen JB, et al
    DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2026 Mar 20:S2588-9311(26)00066.
    PubMed         Abstract available
    
    

    
    Front Immunol

19. TORNESELLO ML, Piccirillo MC, Tambaro R, Simeon V, et al
    Effect of co-occurring mutations in TP53 gene and TERT promoter on the survival of bladder cancer patients.
    Front Immunol. 2026;17:1771897.
    PubMed         Abstract available
    
    

    
    Histol Histopathol

20. HASHIMOTO M, Fukiage K, Minami T, De Velasco MA, et al
    Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: A Review.
    Histol Histopathol. 2026;41:545-552.
    PubMed         Abstract available
    
    

    
    Hu Li Za Zhi

21. LIU MY, Lin SY
    [Caring for a Patient With Rare Urachal Carcinoma and Facilitating Family Medical Decision-Making: A Case Report].
    Hu Li Za Zhi. 2026;73:e26213.
    PubMed         Abstract available
    
    

    
    Int Braz J Urol

22. SUARTZ CV, de Carvalho PRS, Freitas RA, de Souza AM Neto, et al
    The Perioperative Revolution in Muscle-Invasive Bladder Cancer - Progress, Caution, and the Latin American Perspective.
    Int Braz J Urol. 2026;52:e20260158.
    PubMed        
    
    

    
    Int J Biol Macromol

23. ULLAH A, Liu X, Zeng Y, Zhou C, et al
    Red ginseng polysaccharide targets the PI3K/AKT/mTOR pathway to induce mitochondrial apoptosis in bladder cancer.
    Int J Biol Macromol. 2026 Mar 19:151524. doi: 10.1016/j.ijbiomac.2026.151524.
    PubMed         Abstract available
    
    

    
    Int J Hyperthermia

24. GONDA M, Kawai N, Ishikawa D, Aoki M, et al
    Enhanced magnetic hyperthermia using anti-PD-L1 antibody-conjugated magnetoliposomes in a murine subcutaneous bladder cancer model.
    Int J Hyperthermia. 2026;43:2645413.
    PubMed         Abstract available
    
    

    
    Int J Nanomedicine

25. ZHANG X, Wu X, Du J, Mei J, et al
    Gold Nanoparticles in Bladder Cancer Applications: A Paradigm Shift from Diagnostic Tools to Integrated Theranostic Platforms.
    Int J Nanomedicine. 2026;21:575926.
    PubMed         Abstract available
    
    

    
    Int J Urol

26. SHINOHARA M, Yamamoto H, Kawashima Y, Sekine Y, et al
    Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
    Int J Urol. 2026;33:e70425.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

27. GUO C, Wei J, Wang Y, Zhang L, et al
    Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis.
    Int Urol Nephrol. 2026 Mar 25. doi: 10.1007/s11255-026-05110.
    PubMed         Abstract available
    
    

    
    Ir Med J

28. O'MAHONY CJ, Low E, Lynch OE, Daly K, et al
    Investigation of non-visible haematuria in a tertiary urology service.
    Ir Med J. 2026;119:41.
    PubMed         Abstract available
    
    

    
    J Int Med Res

29. CHAN KH, Cen P, Shu T, Canfield S, et al
    Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.
    J Int Med Res. 2026;54:3000605261430450.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

30. KORONICA R, De Leonardis F, Servedio M, Novielli C, et al
    Ifosfamide-Induced Encephalopathy in a Very Young Child With Rhabdomyosarcoma: Case Report and Literature Review.
    J Pediatr Hematol Oncol. 2026;48:139-141.
    PubMed         Abstract available
    
    

    
    J Toxicol Environ Health A

31. DE SOUZA RODRIGUES MR, da Silva IM, Leite Vacario BG, Oliveira Rocha LM, et al
    Genetic variants in 8-oxoguanine DNA glycosylase 1 (OGG1) and X-ray repair cross-complementing protein 1 (XRCC1) and non-genetic factors are associated with bladder cancer susceptibility and prognosis in a Brazilian population.
    J Toxicol Environ Health A. 2026 Mar 25:1-13. doi: 10.1080/15287394.2026.2647858
    PubMed         Abstract available
    
    

    
    J Urol

32. PRASAD SM, Shishkov D, Mihaylov NV, Genov P, et al
    UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.
    J Urol. 2026 Mar 25:101097JU0000000000005041. doi: 10.1097/JU.0000000000005041.
    PubMed         Abstract available
    
    

    
    JCO Oncol Pract

33. XUE Z, Qie Y, Liang S, Li R, et al
    Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.
    JCO Oncol Pract. 2026 Mar 26:OP2501242. doi: 10.1200/OP-25-01242.
    PubMed         Abstract available
    
    

    
    Lakartidningen

34. LIEDBERG F, Holmberg L, Jarvholm B, Liv P, et al
    [Why has bladder cancer incidence not decreased like in lung cancer?].
    Lakartidningen. 2026;123:25097.
    PubMed         Abstract available
    
    

    
    Minerva Urol Nephrol

35. ARTILES MEDINA A, Aumatell J, Gonzalez-Padilla DA, Pichler R, et al
    The updated 2021 EAU risk groups for non-muscle-invasive bladder cancer: what have we learned four years after implementation?
    Minerva Urol Nephrol. 2026 Mar 24. doi: 10.23736/S2724-6051.26.06915.
    PubMed        
    
    

    
    Mol Imaging Biol

36. AVILEZ ND, Tineo RN, Rodrigues JT, Ottaiano AD, et al
    Comparison of [(18)F]FDG and [(18)F]PSMA-1007 PET/CT in the Evaluation of Muscle-Invasive Bladder Cancer: A Pilot Feasibility Study.
    Mol Imaging Biol. 2026 Mar 23. doi: 10.1007/s11307-026-02085.
    PubMed         Abstract available
    
    

    
    Nat Commun

37. SINGH AK, Praharaj M, Lombardo KA, Yoshida T, et al
    Retraction Note: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer.
    Nat Commun. 2026;17:2707.
    PubMed        
    
    

    
    Oncogene

38. HU H, Zhan X, Xiong Y, Yuan R, et al
    Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A.
    Oncogene. 2026 Mar 24. doi: 10.1038/s41388-026-03730.
    PubMed         Abstract available
    
    

    
    Res Rep Urol

39. PEYTON CC, Dhanda R, Burke T, Tsurutis V, et al
    Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.
    Res Rep Urol. 2026;18:591097.
    PubMed         Abstract available
    
    

    
    Scand J Urol

40. VENHOMAA T, Nikulainen I, Bobjer J, Blackberg M, et al
    Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study.
    Scand J Urol. 2026;61:72-79.
    PubMed         Abstract available
    
    

    
    Sci Rep

41. ERGUL RB, Kucukgergin C, Cincin ZB, Cakmakoglu B, et al
    Genome-wide transcriptional profiling identifies molecular markers associated with early carcinogenesis in high-grade bladder cancer.
    Sci Rep. 2026 Mar 26. doi: 10.1038/s41598-026-36530.
    PubMed        
    
    

    
    Support Care Cancer

42. KESSLER ER, Hoover K, Coats H, Fischer SM, et al
    Use of a Delphi process to formulate a pragmatic framework for care planning in older adults with advanced bladder cancer.
    Support Care Cancer. 2026;34:366.
    PubMed         Abstract available
    
    

    
    Surg Today

43. TOKUNAGA R, Yamauchi T, Den H, Omotaka S, et al
    Epidemiology and treatment patterns of urachal remnants in adult patients with omphalitis: a nationwide claims-based study in Japan.
    Surg Today. 2026;56:436-444.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

44. XU MC, Sandberg ML, Childs DD, Cengiz TB, et al
    Synergy of PET and MR imaging in the local and regional staging of bladder cancer.
    Ther Adv Urol. 2026;18:17562872261430967.
    PubMed         Abstract available
    
    

    
    Urol Oncol

45. LEE NJ, Polverino F, Quarta L, Filzmayer M, et al
    Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy.
    Urol Oncol. 2026 Mar 22:111076. doi: 10.1016/j.urolonc.2026.111076.
    PubMed         Abstract available
    
    
46. KOLANUKUDURU KP, Ben-David R, Hug B, Eraky A, et al
    Therapeutic efficacy of Gemcitabine/Docetaxel maintenance in patients with non-muscle-invasive bladder cancer receiving initial Bacillus Calmette-Guerin induction.
    Urol Oncol. 2026 Mar 23:111078. doi: 10.1016/j.urolonc.2026.111078.
    PubMed         Abstract available
    
    

    
    Urologie

47. NIEGISCH G, Gakis G, Ohlmann CH, Knuchel-Clarke R, et al
    [Perioperative therapy for muscle-invasive bladder cancer-current treatment concepts].
    Urologie. 2026 Mar 25. doi: 10.1007/s00120-026-02810.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum